ABSTRACT Background: Studies of zinc as an adjunct to treatment of severe pneumonia in children have shown mixed results, possibly because of poor information on zinc status and respiratory pathogens. Objective: We evaluated the effect of zinc given with standard antimicrobial treatment on the duration of respiratory signs in children with severe pneumonia. Zinc status and pathogens were assessed. Design: Children aged 2-59 mo with severe pneumonia who were admitted to the main children's hospital in Quito, Ecuador, were given standard antibiotics and randomly allocated to receive zinc supplements twice daily or a placebo. Measurements included anthropometric variables, breastfeeding, hemoglobin, plasma zinc, and common bacteria/viral respiratory pathogens. The primary outcome was time to resolution of respiratory signs. The secondary outcome was treatment failure. Results: We enrolled 225 children in each group. There was no difference between groups in time to resolution of respiratory signs or treatment failure; pathogens were not associated with outcomes. Tachypnea and hypoxemia resolved faster in older children (P = 0.0001) than in younger ones. Higher basal zinc concentration (P = 0.011) and better height-for-age z score (HAZ) (P = 0.044) were associated with faster resolution of chest indrawing. Better weight-for-height z score (WHZ) (P = 0.031) and HAZ (P = 0.048) were associated with faster resolution of tachypnea. Increased C-reactive protein was associated with a longer duration of tachypnea (P = 0.044). Conclusions: Zinc did not affect time to pneumonia resolution or treatment failure, nor did type of respiratory pathogens affect outcomes. Higher basal zinc and better HAZ and WHZ were associated with reduced time to resolution of respiratory signs. These results suggest the need for prevention of chronic zinc deficiency and improvement of general nutritional status among Ecuadorian children. This trial was registered at www.clinicaltrials.gov as NCT 00513929. Am J Clin Nutr 2014;99:497-505.
INTRODUCTION
Community-acquired pneumonia is a major cause of morbidity and mortality in children in resource-limited countries (1, 2) and is responsible for w18% of deaths in children ,5 y of age (1.4 million deaths/y) (2) . Zinc, critical for healthy growth and immune function (3) and commonly deficient in low-income countries (4) , can improve growth and reduce the frequency and severity of diarrhea and acute lower respiratory tract infections (ALRIs) 4 , including pneumonia in children (5) (6) (7) (8) . Whereas zinc is an important adjunct to diarrhea treatment, reducing time to recovery among children aged 6 mo to 5 y (9), trials of zinc in children hospitalized with severe pneumonia have yielded mixed results (10) (11) (12) (13) (14) (15) . In a trial conducted in children aged 2-23 mo in Bangladesh, zinc reduced the duration of clinical manifestations of severe pneumonia, including chest indrawing, tachypnea, hypoxia, and length of hospitalization (12) . Another study in Kolkata, India, found that short-course zinc supplementation given to children with severe ALRI significantly reduced fever duration and very ill status in boys but not girls (11) . However, studies in India and Nepal found no benefits of zinc supplementation in children with pneumonia (13, 14) . Inadequate statistical power, variations in pneumonia case definitions, methodologic differences, and regional differences in undernutrition and zinc deficiency may explain these conflicting results. In addition, given the suggestion in the India study that bacterial infection might influence the treatment effect of zinc and even lengthen duration of hospitalization (13, 16) , pneumonia etiology has been discussed as an explanation of these conflicting findings.
Given these inconsistent results, and a lack of prior studies in Latin America where zinc deficiency is widespread (4), we hypothesized that adjunctive zinc supplementation for treatment of pneumonia would reduce both duration of time to resolution of symptoms and treatment failures. Given inconclusive evidence that the impact of zinc supplementation is etiology dependent (16) and limited data that zinc mediates antiviral activity on respiratory syncytial virus (RSV) by altering cellular capacity to support RSV replication (17) , a secondary hypothesis was that this impact would be etiology independent. To test these hypotheses, we conducted a double-blind, placebo-controlled, randomized trial in Quito, Ecuador, which is an ideal location because severe pneumonia in young children represents a major health threat (18) , stunting is common (19) , and nearly one-third of children suffer from zinc deficiency (20) .
SUBJECTS AND METHODS
This study was a randomized, parallel group, double-blind, placebo-controlled clinical trial in children with severe pneumonia designed to measure the efficacy of daily zinc administration until hospital discharge on the duration of pneumonia symptoms, including hypoxemia and treatment failure. It was conducted from February 2008 to April 2010 in Quito, Ecuador, at the Baca Ortiz Children's Hospital, the main pediatric referral hospital in Ecuador. Baca Ortiz has w130,000 outpatient and emergency room consultations annually, and ALRI is the most common reason for hospitalization.
The Ethics Committee of the Corporación Ecuatoriana de Biotecnología and the Boston University Institutional Review Board approved the trial. The study was registered at www.clinicaltrials. gov before starting enrollment (NCT 00513929). Written informed consent was obtained from each child's parent or care provider. The Ethics Committee of the Corporación Ecuatoriana de Biotecnología supervised the study to ensure that study procedures were followed and served as the Data Safety Monitoring Board (DSMB). The DSMB conducted 2 interim reviews of safety data and a blinded interim analysis at one-and two-thirds' enrollment. At each review, the DSMB recommended that the study continue without changes until the number of enrolled children met the planned sample size because there was no significant statistical difference in the outcomes between groups.
Eligibility criteria, definitions, and randomization
Children aged 2-59 mo with severe pneumonia admitted to the Baca Ortiz Children's Hospital, whose parents provided written informed consent, were eligible for participation. Children suffering from marasmus, kwashiorkor, measles, pneumonia resulting from reported aspiration, hepatic or renal disease, neurologic disorders, acute diarrhea with dehydration, other viral infections, sepsis, congenital abnormalities, complicated pneumonia, severe anemia (hemoglobin ,8 g/dL), inability to take fluids, whose parents refused to provide informed consent, and who had been treated with antibiotics for ˃24 h before admission were excluded.
In the emergency room, a resident physician exclusively dedicated to the screening of potential study subjects evaluated each child with respiratory symptoms. If the child was eligible, a senior study physician performed a thorough clinical examination and rapid hemoglobin test. If pneumonia was confirmed and the child met no exclusion criteria, the study physician enrolled the child after written informed consent was obtained from the care provider.
At enrollment, study physicians collected information on demographic characteristics, current illness, and medical history. A detailed clinical evaluation was performed including weight, height, respiratory rate, oxygen saturation (SpO 2 ), axillary temperature, and chest indrawing. A calibrated scale (Detecto) was used to measure the child's weight while wearing minimal clothing. Length or height was measured with a footboard (children aged ,2 y) or vertical tape measure (children aged $2 y). Additional baseline testing included the following: 1) collection of blood to measure C-reactive protein (CRP), plasma zinc, whole-blood polymerase chain reaction (PCR) for Streptococcus pneumoniae and Hemophilus influenzae type b (Hib), 2) pulse oximetry, 3) nasopharyngeal aspirate for PCR analysis of atypical bacteria and viruses, and 4) chest X-ray.
Severe pneumonia was based on a modified version of the WHO definition (21) and included the presence of cough and/or chest wall indrawing, tachypnea (.50 breaths/min in children from 2 to ,12 mo of age, .40 breaths/min in children from 12 to 59 mo), hypoxemia (SpO 2 ,90%), and at least one of the following by thoracic auscultation: rales, diminished breath sounds, bronchial breath sounds, or pleural rub.
Criteria for clinical resolution of pneumonia were remission of tachypnea and hypoxemia for at least 12 h. In children with chest wall indrawing at baseline, resolution also included absence of this sign for at least 12 h. Treatment failure within the first 7 d was defined as follows: 1) clinical deterioration any time after enrollment, including chest indrawing, at 72 h; 2) inability to take oral medication because of persistent vomiting; 3) modification of initial antibiotic choice; or 4) death.
The Universidad Central del Ecuador, Escuela de Quimica manufactured the zinc and placebo syrups, which had similar appearance, color, odor, and mint flavor. Bottles with syrup were assigned 1 of 4 alphabetical codes (2 corresponding to zinc and placebo, respectively) by the manufacturer. A computer randomization list was generated and converted into a sequence of bottles containing the therapeutic regimen by a statistician who was blinded to the codes. Once an eligible child was identified, the next bottle in the sequence was opened, and the corresponding regimen provided to the child. The local ethics committee held the blinded randomization codes in a secure place. The study code was broken after all data were entered and initial blinded analyses had been performed. Two batches of zinc/placebo were manufactured (one per year), with blinded quality control to determine the zinc concentration. Sealed laboratory reports were sent to the president of the ethics committee for verification of appropriate concentrations.
Intervention
Children were prescribed antibiotics and were randomly allocated to receive 20 mg elemental zinc or placebo, in 2 doses per day to minimize adverse gastrointestinal effects. The active substance concentration was 10 mg elemental zinc (zinc sulfate) in 5 mL. Five milliliters of syrup were administered to each participant twice daily (at noon and at midnight) in addition to standard antibiotic treatment. The same dosing regimen (10 mg of zinc twice a day) was used by the previous studies described above (11) (12) (13) . If the child vomited within 30 min, the dose was repeated. Care providers and study team members were blinded to the allocation.
Participants were given standard antimicrobial regimens based on national guidelines, which is standard practice in pediatric hospitals in Ecuador (22) . Children started with regimen number 1 according to his or her age (ampicillin if ,2 y, penicillin if $2 y). In cases of deterioration within 48 h or no improvement, the treatment shifted to the next regimen. However, if deterioration was rapid, any other standard regimen was selected. Additional therapeutic measures were provided as needed, including oxygen, intravenous hydration, nothing by mouth other than the study supplement if the respiratory rate was .60/min, and salbutamol nebulizer every 6 h for wheezing.
Follow-up procedures
Study physicians performed standard procedures for all clinical assessments every 6 h. When the participant was calm, respiratory rate was determined by counting respiratory abdominal movement for 60 s. Lower chest wall indrawing was evaluated by direct observation. SpO 2 was measured with a pulse oximeter (OxiMax N-65; Nellcor), which performs an internal calibration when turned on and when the oxygen transducer is applied. For readings ,90%, the observer reapplied the transducer to the child and repeated the procedure. An average of 2 measurements was documented.
For participants receiving oxygen therapy, we withdrew the oxygen cannula for 2 min and assessed respiratory rate, lower chest indrawing, and pulse oximetry. When oxygen withdrawal could not be tolerated, it was immediately readministered.
Axillary temperature was measured with digital electronic thermometers, confirmed by second recordings. Thorough examinations were performed every 24 h. At remission of tachypnea, hypoxemia, and chest wall indrawing, blood was drawn for measurement of final plasma zinc concentration.
In cases of suspected treatment failures, the principal investigator or a senior pediatrician was contacted to confirm the treatment failure. At this time, antibiotic therapy was changed and another appropriate therapy was started. All cases of treatment failure were followed up until resolution.
Laboratory analyses
At enrollment and time of remission, blood samples (4 mL for the basal and 3 mL for the final sample) were obtained by venipuncture at the forearm. Because the time of enrollment and pneumonia resolution were different for each child, it was not possible to obtain samples under fasting conditions. Hemoglobin was measured at enrollment by finger prick by using a portable HemoCue Hb 2011 machine. A nasopharyngeal aspirate was obtained and divided into 2 samples: one for bacteria detection and another for viruses. Samples were stored at -208C until processing.
Standard chest X-rays were obtained at enrollment by using a Gentron 650 radiographic machine (General Electric) and interpreted by an experienced senior radiologist.
A photometric-turbidimetric test was performed for determination of plasma CRP. The assay Dimension Clinical Chemistry System Flex reagent cartridge (Siemens) was performed according to the manufacturer's instructions.
For plasma zinc analysis, blood was collected in standard disposable plastic syringes (nonheparinized) with stainless steel needles. Blood was transferred to a polystyrene tube containing zinc-free heparin (300 mL/10 mL blood). Blood samples were centrifuged immediately to obtain plasma, which was stored in nitric acid-treated Eppendorf tubes at -208C until analysis. Zinc concentrations were measured by atomic absorption spectrometry at the Chemistry School of Central University, as previously described (23) . Zinc deficiency was defined as a plasma concentration ,70 mg/dL after adjustment by CRP concentration (24) .
Microbiological studies
The presence of Mycoplasma pneumoniae, Chlamydiophila pneumoniae, and human metapneumovirus (hMPV); RSV; parainfluenza virus 1, 2, 3; influenza A virus; influenza B virus; and adenovirus was determined by PCR in nasopharyngeal aspirates (F Sempértegui, B Estrella, O Rodríguez, L Ortíz, C Cruz, DH Hamer, unpublished observations, 2013). Plasma PCR was performed for detection of S. pneumoniae and Hib.
Sample size
In previous research at the Baca Ortiz Children's Hospital, the average (6SD) duration of hospitalization of children with pneumonia was 5.07 6 2.87 d (22) . With 80% power, a 2-sided significance of 0.05, and a mean reduction in duration of pneumonia signs by 1 d (12), the required sample size was 174 children per study arm. Assuming a 15% loss to follow-up (22) , the total sample size for this primary outcome was 200 children per group. Assuming treatment failure of 20% in the placebo group (22), a 50% reduction in treatment failure in zinc-supplemented children, 80% power, and 2-tailed a of 0.05, the required sample size was 199 children in each group. With no published data on the etiologydependent duration of pneumonia in young children, we assumed a similar duration of pneumonia episode for all etiologies.
Because of a very heavy volume of pneumonia-related hospitalizations in the winter of 2008, several participants were discharged before completion of all study procedures. The Boston University Institutional Review Board and local ethics committee recommended increasing the sample size to 450 or 225 per group to ensure complete data on 200 children per group, the original sample size.
Statistical analysis
Project-specific case report forms were used for data collection, all of which were standardized in a previous vitamin A study (22) . All forms were checked twice weekly by the study supervisor for completion and discrepant, inappropriate, and illogical responses. Double data entry was performed with Microsoft Access 2000 (Microsoft Corporation). Microsoft Excel was used for validation and cleaning, and SPSS (version 11.5.0; SPSS, Inc) was used for all analyses.
Descriptive statistics were calculated for all baseline measurements. Because decreased plasma zinc concentration has been found during acute infections in children (20, 24) , we performed linear regression between CRP and plasma zinc concentrations to derive the constant for adjusting the baseline zinc concentration. Intent-to-treat and per-protocol analyses were performed. Zinc and placebo groups were compared with regard to primary and secondary outcome variables: time to remission (in h) of the 2 clinical signs together (tachypnea and hypoxemia), the 3 signs together when chest wall indrawing was present, and treatment failure. The 2 groups were also compared for time to remission of each sign (tachypnea, hypoxemia, and chest wall indrawing). Differences between means and proportions were analyzed by using Student's t and chi-square tests, respectively, with level of significance at #0.05. The log-rank test for homogeneity for Kaplan-Meier survival curves was used to test differences in time to resolution of all 3 signs.
To assess the effect of zinc on hours to resolution of clinical signs of pneumonia, while controlling for predictor variables [age, sex, breastfeeding, adjusted basal zinc concentration, basal CRP concentration, height-for-age z score (HAZ), weight-forheight and weight-for-length z scores (WHZ and WLZ, respectively), hemoglobin, and presence of pathogens] as potential confounders, we developed a multiple linear regression model. To evaluate the effect of zinc on treatment failure, we developed a logistic regression model that controlled for the same predictor variables. Associations between the intervention and outcomes of interest in the regression models were considered to be significant at P # 0.05.
RESULTS
Of 2768 screened potential study candidates, 662 children met the eligibility criteria, and 450 children were enrolled with 225 children assigned to each study group-zinc and placebo. The principal reasons for exclusion were ambulatory treatment, admission to nonstudy wards, no study ward beds available, refusal of parental consent, and readmission for pneumonia (Figure 1) . During the study, 69 children (15.3%) did not complete all study procedures because of early hospital discharge due to ward overcrowding, parental requests for discharge against medical advice, and development of complicated pneumonia. There were 4 deaths, 1 in the intervention group and 3 in the placebo group. Children with incomplete follow-up were distributed evenly in both groups (Figure 1) . Five children in the zinc group and 4 in the placebo group who were referred immediately after enrollment to other wards because of either erroneous enrollment or per hospital request were not included in the analysis. There were no significant differences between zinc and placebo groups with regard to baseline variables in children who did not complete all study procedures.
Of the 450 children enrolled, 40.4% were girls and 59% were infants aged 2-12 mo. Eighteen percent of children were underweight, 19% were stunted, and 14% were wasted. At enrollment, no significant differences were observed between the zinc and placebo groups in baseline characteristics, including zinc deficiency (plasma zinc concentration #70 mg/dL), respiratory signs, chest X-ray findings, or pathogens (bacteria or virus) ( Table 1 ). 
Pneumonia pathogens
A total of 407 samples (404 plasma and 407 nasopharyngeal samples) were analyzed for determination of all pathogens except for Hib (299 tested, 0 positive). Pathogens were detected in 297 of 407 samples (73%) including viruses in 63% (257 of 407) and bacteria in 2.7% (11 of 406). Some samples were positive for both viruses and bacteria (7.1%; 29 of 407). Two or more pathogens were identified in 34.7% (103 of 297) of children with pathogenpositive results. RSV was the most frequently identified virus (39.2%), followed by hMPV (17.5%) and adenovirus (15.3%). S. pneumoniae was the most prevalent bacteria (9.2%).
There were no differences in the frequency or type of pathogen between the zinc and placebo groups. Moreover, baseline-adjusted zinc concentration and zinc deficiency were not associated with specific pathogens.
Clinical findings
There were no significant differences between zinc and placebo groups for the primary outcome: time to remission of tachypnea and hypoxemia ( Figure 2) . Moreover, there were no significant differences in the duration of individual respiratory signs ( Table  2 ) or in prevalence of treatment failure (placebo compared with zinc: 34.4% compared with 34.5%; OR: 1.00; 95% CI: 0.68, 1.50) ( Table 3) . Clinical deterioration and change in antibiotics were the most common causes of treatment failure; there was no difference in the incidence of these 2 causes between the 2 groups.
There were no differences in the time to resolution of respiratory signs either combined or individually between the zinc and placebo groups when stratified by the presence of specific pathogens or by the presence of virus or bacteria at enrollment (data not shown).
Predictors of primary outcomes
Multiple linear regression models showed no effect of zinc on time to remission of the 2 clinical signs together when predictor variables were controlled for. However, higher age was associated with decreased time to resolution of tachypnea and hypoxemia together ( Table 4) . The results were similar when assessing remission of the 3 signs together (including chest wall indrawing) (data not shown).
Higher baseline zinc concentration was associated with a reduction in time to remission of chest indrawing (P = 0.011) ( Table  5 ). Higher HAZ was also associated with reduction in time to remission of chest indrawing (P = 0.044). There was no significant interaction between basal plasma zinc and HAZ on time to resolution of chest indrawing. Better WHZ/WLZ was associated with a reduction in time to remission of tachypnea (P = 0.031). Better HAZ was also associated with a reduction in time to remission of tachypnea (P = 0.048). Higher CRP concentration was associated with increased time to resolution of tachypnea (P = 0.044). Breastfeeding, exclusive or nonexclusive, was associated with a trend toward reduced time to remission of chest indrawing (P = 0.074). The analysis of time to remission of hypoxemia showed that only age was significantly associated with this outcome.
DISCUSSION
Zinc as an adjunct to the standard treatment of severe pneumonia in hospitalized Ecuadorian children had no effect on time to resolution of clinical signs or the proportion with treatment failure. Children with better baseline zinc status had more rapid resolution of chest indrawing, which was independent of the intervention. Previous studies, which also failed to show that zinc supplements reduced time to resolution, did not provide data on baseline zinc status or the association of baseline zinc status with time to resolution of pneumonia (12) (13) (14) (25) (26) (27) (28) (29) (30) . After adjusting for inflammation, we found that .40% of enrolled children were zinc deficient. Because plasma zinc concentrations significantly increased in the supplemented group, the lack of effect of zinc on duration of respiratory signs suggests that the systemic impact of chronic zinc deficiency, including the impairment of immune response, is not reversed with short-term supplementation.
Most previous therapeutic trials of zinc in children with pneumonia did not identify pathogens associated with episodes of severe pneumonia. Although Coles et al (16) suggested a pathogen-dependent effect of zinc, they used CRP as a proxy for bacterial compared with viral infection. This inflammatory marker is nonspecific and has not been shown to reliably distinguish between these 2 pneumonia etiologies (31) (32) (33) . We found that higher CRP was associated with delayed remission of tachypnea. Higher CRP may be associated with more severe disease and therefore could serve as a nonspecific marker of risk for prolonged illness. We did not find any differences in the prevalence or type of pathogen between the 2 groups. Furthermore, time to resolution of pneumonia episodes did not differ between groups for each of the most frequent pathogens (RSV, hMPV, adenovirus, and S. pneumoniae). Therefore, these findings suggest that there is not a pathogen-specific effect of zinc on pneumonia.
We found that better basal plasma zinc concentration was associated with shorter time to remission of chest indrawing. This suggests that zinc-deficient children suffer from impaired immune function, which affects their ability to fight infection, as has been reported previously (3, 34, 35) . In fact, zinc supplementation has been shown to prevent pneumonia episodes (7, 8, 36) . Thus, a policy aimed at improving the zinc status of young children continues to be a high priority in developing countries, especially where dietary zinc intake is limited and phytate intake is high, as in Andean countries.
We also found that better HAZ was associated with reduced time to remission of chest indrawing and tachypnea, in contrast to previous zinc treatment studies (12) (13) (14) (25) (26) (27) (28) (29) . Although there was no significant interaction between HAZ and basal plasma zinc in reducing time to remission of chest indrawing, it is possible that nutritional status could be improved either via a direct zincmediated effect on growth (5) or via rapid clearance of pathogens (to prevent their deleterious effect on growth). In fact, we have found that linear growth is significantly reduced by one or more episodes of pneumonia in young children (F Sempértegui, B Estrella, J Egas, et al, unpublished observations, 2013). The association between better WHZ and faster resolution of tachypnea suggests that acute malnutrition could lead to increased vulnerability of children to pneumonia. This finding is consistent with a study from Bangladesh, which found that wasted children have impaired immune function and are at higher risk of upper respiratory infections (37) .
The association between basal zinc concentration and time to remission of respiratory signs does not necessarily imply a direct cause and effect. Similarly, the association between nutritional status (HAZ, WHZ) and duration of respiratory signs is suggestive of an overall effect of generalized nutritional status, which, in the case of stunted or wasted children, is likely to be associated with multiple micronutrient deficiencies as a causal factor. Although there was a trend to faster resolution of chest indrawing only in breastfed children, it is important to emphasize that breastfeeding has been found to be associated with improved innate immunity (38) and interferon production in children with influenza (39) .
Strengths of this study included its adequate power, careful attention to allocation and blinding, close monitoring of respiratory signs, training of the study team, and standardization of measurement techniques. The study also benefited from inclusion of critical baseline variables to control for potential confounders of the effect of zinc. Weaknesses included a dropout rate that was higher than expected, especially during the initial weeks of the study, because of overcrowded wards. Additional limitations were related to the lack of certain routine bacteriologic test procedures (blood cultures, induced-sputum Gram stain and culture). In conclusion, we found no beneficial effect of zinc on the duration of respiratory signs or risk of treatment failure. Although previous studies that failed to show a benefit of zinc in the treatment of pneumonia had emphasized the lack of baseline information on zinc status and associated pathogens, our study suggests that these variables do not explain the absence of benefit. The association of zinc deficiency and stunting/wasting with prolongation of respiratory rates and hospitalization suggests a need for greater efforts directed at improving the overall nutritional status of Ecuadorian children, in particular their zinc status.
